Logo
Website CRS  >  Search
Search
    Search for:
     

    Advanced search

    Rules:

    Only words with 2 or more characters are accepted
    Max 200 chars total
    Space is used to split words, "" can be used to search for a whole string (not indexed search then)
    AND, OR and NOT are prefix words, overruling the default operator
    +/|/- equals AND, OR and NOT as operators.
    All search words are converted to lowercase.

    Search for "biosimilar"

    Displaying results 1 to 5 out of 5

      News 4 81%
      News 4 Biosimilar Case Study The following case study had been realised between November 2011 until May 2012. CRS put lot of effort in the management of diverse ...
      Size: 29 K - Created: 18-11-12 - Modified: 02-08-19 10:27
    Path: /Home/News 4

      Medical Writing 76%
      ... (CTD)   Development and therapeutic areas: Phase I Clinical pharmacology studies – pharmacokinetics and pharmacodynamics Biologics and biosimilars
      Size: 31 K - Created: 18-11-12 - Modified: 02-08-19 10:27
    Path: /Services/Medical Writing

      Trial Expertise 67%
      ... or more and its resources guarantee the quickest possible performance. CRS has conducted trials in all compound classes including hormones and biosimilars and all modes of administration such as oral, transdermal, buccal and sublingual. In 2008, 2009, 2010, 2011 and 2014, the FDA performed ...
      Size: 34 K - Created: 18-11-12 - Modified: 02-08-19 10:27
    Path: /Expertise/Trial Expertise

      2010-2019 55%
      ... on the Pharmacokinetics of Sorafenib in Healthy Male Subjects Thyroid. July 2017, ahead of print. Forst T , Plum-Mörschel L: Insulin-Biosimilars – Neu und doch vertraut ? Kompendium Biosimilars 2017 Forst T : Adjuvante Therapie durch Hemmung der Natrium-Glukose-Transporter bei Patienten mit einem Diabetes mellitus Typ 1 Diabetes ...
      Size: 67 K - Created: 09-11-15 - Modified: 14-08-19 14:46
    Path: /Expertise/Published Expertise/2010-2019

      2000 – 2009 53%
      ... PFA-100®. Platelets in press 2009. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23(1):43-51. Leroux-Roels ...
      Size: 52 K - Created: 09-11-15 - Modified: 02-08-19 10:27
    Path: /Expertise/Published Expertise/2000 – 2009

    Callback
    FooterEnd